For the quarter ending 2025-09-30, LCTX had -$1,798K decrease in cash & cash equivalents over the period. -$3,628K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss attributable to lineage | -29,781 | -34,603 |
| Net income (loss) attributable to noncontrolling interest | 29 | 96 |
| Issuance costs for common stock warrant liabilities | 0 | 183 |
| Loss on impairment of intangible asset | 0 | 14,840 |
| Loss on marketable equity securities, net | 6 | -7 |
| Accretion of income on marketable debt securities | 0 | 10 |
| Foreign currency remeasurement and other loss | - | 1,455 |
| Depreciation and amortization expense | 178 | 335 |
| Change in right-of-use assets and liabilities | 47 | -88 |
| Amortization of intangible assets | 0 | 0 |
| Stock-based compensation | 1,199 | 2,455 |
| Change in fair value of warrant liability | 26,557 | 10,435 |
| Foreign currency remeasurement | 1,721 | - |
| Accounts receivable | -130 | -381 |
| Prepaid expenses and other current assets | 194 | -1,271 |
| Accounts payable and accrued liabilities | 271 | -459 |
| Deferred revenue | -1,780 | -3,813 |
| Net cash used in operating activities | -3,616 | -10,425 |
| Proceeds from the sale of marketable equity securities | 0 | 0 |
| Purchases of marketable debt securities | 0 | 0 |
| Maturities of marketable debt securities | 0 | 2,000 |
| Purchase of equipment | 12 | 111 |
| Net cash (used in) provided by investing activities | -12 | 1,889 |
| Proceeds from employee options exercised | 487 | 0 |
| Proceeds from exercise of warrants | 319 | - |
| Common shares received and retired for employee taxes paid | 0 | 15 |
| Proceeds from sale of common shares, net of offering costs-At The Market | 1,276 | 0 |
| Proceeds from sale of common shares, net of offering costs-Direct Financing | 0 | 0 |
| Proceeds from sale of common shares, net of offering costs-Warrants Under Registered Direct Financing | 0 | 5,232 |
| Payment of financed insurance premium | 232 | 452 |
| Payment of finance lease liabilities | 16 | 28 |
| Net cash provided by financing activities | 1,834 | 4,737 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -4 | 220 |
| Net decrease in cash, cash equivalents and restricted cash | -1,798 | -3,579 |
| Cash and cash equivalents at beginning of period | 46,354 | - |
| Cash and cash equivalents at end of period | 40,977 | - |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)